Eagle Pharmaceuticals (EGRX)

$1.65 -0.15 (-8.33%)
Market Cap 23.38M
Revenue (ttm) 316.61M
Net Income (ttm) 35.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 11.26%
Debt to Equity Ratio 0.28
Volume 501
Avg Vol 7,928
Day's Range N/A - N/A
Shares Out 12.99M
Stochastic %K 82%
Beta 0.83
Analysts Strong Buy
Price Target $17.00

Company Profile

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 201 326 5300
Address:
50 Tice Boulevard, Suite 315, Woodcliff Lake, United States
worldslargestpenguin
worldslargestpenguin Jun. 6 at 9:57 PM
$EGRX just doing the math today on the trailing twelve month sales here.....giving $EGRX a gross to net discount of 50% here cause fuck PBMs, Ryanodex is still performing after going generic 24M net, Belrapzo 29M net protected till 2031, Bendeka where the royalty is at did 181M net which is 56M net on the royalty so coming back to us in 2H'2027, and Byfavo did 1.5M net............how is this company endangered? seems like continual mismanagemnt im so pissed.....we got to call Nantahala Capital Management and tell them to get this company in gear, office number is 203-909-6430 tell them you are a shareholder and get their pressure on this situation
0 · Reply
11thestate
11thestate Jun. 3 at 2:16 PM
$EGRX Investor reminder. Eagle Pharmaceuticals investors who purchased shares between August 8, 2022, and October 1, 2024 may be eligible to participate in the company's investor settlement. The settlement claims that investors were misled about the commercial prospects of PEMFEXY. After the company lowered guidance and disclosed weaker-than-expected performance, the stock price declined significantly. If you traded $EGRX during that period, it may be worth reviewing your records and claim: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 May. 23 at 8:07 PM
$EGRX @Tresses @worldslargestpenguin @Tresses • …the final stages to launch oncology drug in Q1 2026, managing 4 business deals (505B2, ANDA), supporting entire commercial portfolio for project improvements and managing complex/worldwide phase 2 clinical study execution. • Coordinated a product launch from end to end for a high visibility and key oncology product working with external development group, CMO, multiple contracts testing labs (CTL) that resulted in successful build of supply for product launch • Perform risk management to minimize project risks: Partner with the Project Lead to drive cross-functional discussions around the risks and mitigation plan with positive mindset and transparently communicated and escalated as appropriate.
2 · Reply
11thestate
11thestate May. 21 at 1:49 PM
Eagle Pharmaceuticals ($EGRX) Settlement Approved – $9.5 million Recovery Available The court has approved the $9.5 million settlement between Eagle Pharmaceuticals and its investors over product performance and financial controls . In 2023, the company was accused of failing to disclose slowing sales caused by excess and expired inventory at a key wholesale customer. Following the disclosure, the stock dropped, and investors filed a lawsuit. The settlement has now been finalized and approved by the court. If you held $EGRX during the relevant period, you can review the details and submit a claim. https://11th.com/cases/eagle-investor-suit
0 · Reply
worldslargestpenguin
worldslargestpenguin May. 15 at 9:48 PM
$EGRX bendeka alone is worth at least $30M when it gets returned to them....hopefully Nantahala puts pressure on them when the stand still expires this year
1 · Reply
11thestate
11thestate May. 8 at 1:47 PM
$EGRX — Eagle Pharmaceuticals Agreed to Settle With Investors Eagle Pharmaceuticals has agreed to settle $9.5 million with investors regarding product performance and financial controls related to its cancer drug PEMFEXY. The agreement has already been submitted to the court for final approval. The settlement aims to compensate affected shareholders. If you purchased $EGRX between August 9, 2022 and October 1, 2024, you may be eligible to file a claim and recover part of your losses. You can review the details and submit your claim here: https://11th.com/cases/eagle-investor-suit
0 · Reply
11thestate
11thestate Apr. 17 at 1:44 PM
$EGRX — Eagle Pharmaceuticals reached a tentative settlement Held between 8/9/2022–10/1/2024? Settlement amount still being finalized but your application will be queued. Eagle promoted its chemo drug PEMFEXY as a revenue driver while a key wholesaler was sitting on expiring inventory. When Eagle restated revenue in May 2023, the stock dropped. Investors sued. A settlement was reached. Waiting for court's final approval. ➡️ Apply here: https://11th.com/cases/eagle-investor-suit
0 · Reply
Luckyluciano
Luckyluciano Apr. 16 at 12:58 PM
$EGRX Are these class acyion lawsuits legit or are they scams?
1 · Reply
11thestate
11thestate Apr. 2 at 2:05 PM
$EGRX investors: a new settlement has been reached! Eagle Pharmaceuticals has agreed to settle claims that it misled investors about the performance of its cancer drug PEMFEXY, hiding inventory problems at a key wholesale customer while continuing to report strong demand. Now, investors who were caught holding the bag have a chance to recover. 🗓️ Class Period: August 9, 2022 – October 1, 2024 ⏳ Settlement terms are still being finalized, but you can submit your early claim now. 👉 Submit your application here: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Apr. 1 at 9:10 PM
$EGRX Nantahala and the board trying hard to show court there’s no money here strategically
0 · Reply
Latest News on EGRX
No data available.
worldslargestpenguin
worldslargestpenguin Jun. 6 at 9:57 PM
$EGRX just doing the math today on the trailing twelve month sales here.....giving $EGRX a gross to net discount of 50% here cause fuck PBMs, Ryanodex is still performing after going generic 24M net, Belrapzo 29M net protected till 2031, Bendeka where the royalty is at did 181M net which is 56M net on the royalty so coming back to us in 2H'2027, and Byfavo did 1.5M net............how is this company endangered? seems like continual mismanagemnt im so pissed.....we got to call Nantahala Capital Management and tell them to get this company in gear, office number is 203-909-6430 tell them you are a shareholder and get their pressure on this situation
0 · Reply
11thestate
11thestate Jun. 3 at 2:16 PM
$EGRX Investor reminder. Eagle Pharmaceuticals investors who purchased shares between August 8, 2022, and October 1, 2024 may be eligible to participate in the company's investor settlement. The settlement claims that investors were misled about the commercial prospects of PEMFEXY. After the company lowered guidance and disclosed weaker-than-expected performance, the stock price declined significantly. If you traded $EGRX during that period, it may be worth reviewing your records and claim: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 May. 23 at 8:07 PM
$EGRX @Tresses @worldslargestpenguin @Tresses • …the final stages to launch oncology drug in Q1 2026, managing 4 business deals (505B2, ANDA), supporting entire commercial portfolio for project improvements and managing complex/worldwide phase 2 clinical study execution. • Coordinated a product launch from end to end for a high visibility and key oncology product working with external development group, CMO, multiple contracts testing labs (CTL) that resulted in successful build of supply for product launch • Perform risk management to minimize project risks: Partner with the Project Lead to drive cross-functional discussions around the risks and mitigation plan with positive mindset and transparently communicated and escalated as appropriate.
2 · Reply
11thestate
11thestate May. 21 at 1:49 PM
Eagle Pharmaceuticals ($EGRX) Settlement Approved – $9.5 million Recovery Available The court has approved the $9.5 million settlement between Eagle Pharmaceuticals and its investors over product performance and financial controls . In 2023, the company was accused of failing to disclose slowing sales caused by excess and expired inventory at a key wholesale customer. Following the disclosure, the stock dropped, and investors filed a lawsuit. The settlement has now been finalized and approved by the court. If you held $EGRX during the relevant period, you can review the details and submit a claim. https://11th.com/cases/eagle-investor-suit
0 · Reply
worldslargestpenguin
worldslargestpenguin May. 15 at 9:48 PM
$EGRX bendeka alone is worth at least $30M when it gets returned to them....hopefully Nantahala puts pressure on them when the stand still expires this year
1 · Reply
11thestate
11thestate May. 8 at 1:47 PM
$EGRX — Eagle Pharmaceuticals Agreed to Settle With Investors Eagle Pharmaceuticals has agreed to settle $9.5 million with investors regarding product performance and financial controls related to its cancer drug PEMFEXY. The agreement has already been submitted to the court for final approval. The settlement aims to compensate affected shareholders. If you purchased $EGRX between August 9, 2022 and October 1, 2024, you may be eligible to file a claim and recover part of your losses. You can review the details and submit your claim here: https://11th.com/cases/eagle-investor-suit
0 · Reply
11thestate
11thestate Apr. 17 at 1:44 PM
$EGRX — Eagle Pharmaceuticals reached a tentative settlement Held between 8/9/2022–10/1/2024? Settlement amount still being finalized but your application will be queued. Eagle promoted its chemo drug PEMFEXY as a revenue driver while a key wholesaler was sitting on expiring inventory. When Eagle restated revenue in May 2023, the stock dropped. Investors sued. A settlement was reached. Waiting for court's final approval. ➡️ Apply here: https://11th.com/cases/eagle-investor-suit
0 · Reply
Luckyluciano
Luckyluciano Apr. 16 at 12:58 PM
$EGRX Are these class acyion lawsuits legit or are they scams?
1 · Reply
11thestate
11thestate Apr. 2 at 2:05 PM
$EGRX investors: a new settlement has been reached! Eagle Pharmaceuticals has agreed to settle claims that it misled investors about the performance of its cancer drug PEMFEXY, hiding inventory problems at a key wholesale customer while continuing to report strong demand. Now, investors who were caught holding the bag have a chance to recover. 🗓️ Class Period: August 9, 2022 – October 1, 2024 ⏳ Settlement terms are still being finalized, but you can submit your early claim now. 👉 Submit your application here: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Apr. 1 at 9:10 PM
$EGRX Nantahala and the board trying hard to show court there’s no money here strategically
0 · Reply
11thestate
11thestate Mar. 25 at 2:24 PM
A common question: what about legal fees? Here's how it works: attorney fees in $EGRX settlement are approved separately by the court — and are capped by law. They don't come out of your payout. The fund set aside for investors is exactly that — for investors. If you bought between August 9, 2022, and October 1, 2024, what's waiting for you has nothing to do with what the lawyers earn. Check your eligibility here: https://11th.com/cases/eagle-investor-suit
0 · Reply
11thestate
11thestate Mar. 24 at 3:29 PM
This settlement has no impact on $EGRX stock price. Eagle Pharmaceuticals already reached an agreement with investors. The case is closed. The settlement fund doesn't come from current operations — it comes from a legal process that has already concluded. You can still be a shareholder and file a claim at the same time. They're not mutually exclusive. If you bought between August 9, 2022 and October 1, 2024, check if you qualify: https://11th.com/cases/eagle-investor-suit
0 · Reply
11thestate
11thestate Mar. 20 at 3:13 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there's some good news. $EGRX investors — you might be surprised, but you actually have a chance to recover your losses. Don't miss it: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Mar. 20 at 6:54 AM
$EGRX Chris joined Eagle pharmaceutical after the company was delisted from the Nasdaq and defaulted on its debt with the goal to rebuild the financial organization, get the company current and partner with the CEO and board to drive shareholder value.
3 · Reply
Freddy7672
Freddy7672 Mar. 18 at 8:06 AM
$EGRX thanks to Tariff ea 114 is 5 yrs late.
1 · Reply
Freddy7672
Freddy7672 Mar. 18 at 6:28 AM
$EGRX it
0 · Reply
Freddy7672
Freddy7672 Mar. 18 at 1:47 AM
$EGRX spell wonderful 800% up
0 · Reply
11thestate
11thestate Mar. 17 at 10:28 AM
Don't forget that there is also an important settlement to watch for $EGRX We have every detail, including how investors can get paid: https://11th.com/cases/eagle-investor-suit
0 · Reply
11thestate
11thestate Mar. 10 at 1:46 PM
Imagine buying $EGRX at its peak, only to watch it crash like this — and then finding out there's a way to get some money back. To all $EGRX investors out there, we've got some important news for you: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Mar. 4 at 7:16 AM
$EGRX Nantahala let's go, Chapter 7 or 11 to take her for yourself??
3 · Reply
11thestate
11thestate Feb. 27 at 12:35 PM
$EGRX has agreed to settle with investors over claims that it misled them about product performance and financial controls related to its cancer drug PEMFEXY®. Who’s eligible? Anyone who purchased $EGRX shares between August 9, 2022 and October 1, 2024. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? No payout per share has been announced yet. Can I still file? Yes. When do payouts happen? Typically within 8–12 months after final court approval of the settlement, once the terms are finalized and approved. To file your claim: https://11th.com/cases/eagle-investor-suit
0 · Reply
11thestate
11thestate Feb. 18 at 3:51 PM
Imagine buying $EGRX at its peak, only to watch it tumble — and then learning there may be a way to recover some of your losses. To all $EGRX investors out there, we’ve got some important news for you: https://11th.com/cases/eagle-investor-suit
0 · Reply